pharma · Ovarian Cancer · Breast Cancer · ZNTL
Zentalis Pharmaceuticals (United is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker ZNTL. Primary therapeutic focus areas include Ovarian Cancer, Breast Cancer, High-Grade Serous Ova
Phase 2 · small molecule · Amyloidosis
ZN-d5 is a small-molecule therapeutic candidate developed by Zentalis Pharmaceuticals for the treatment of amyloidosis, a rare disease characterized by abnormal protein folding and accumulation in tissues. The program is currently in Phase 2 development, with a completed Phase 2 trial (NCT05199337) as of September 2024
Internal code ZN-d5-003
ZN-d5 is a small-molecule therapeutic candidate developed by Zentalis Pharmaceuticals for the treatment of amyloidosis, a rare disease characterized by abnormal protein folding and accumulation in tissues. The program is currently in Phase 2 development, with a completed Phase 2 trial (NCT05199337) as of September 2024. Zentalis is pursuing this indication independently without disclosed partnership arrangements. The mechanism of action and specific molecular target remain undisclosed. The Phase 2 completion represents a key inflection point for the program, though detailed efficacy and safety data from the trial have not yet been publicly reported. ZN-d5 enters a competitive landscape that includes both approved therapies and multiple candidates in Phase 3 development, primarily from Alnylam Pharmaceuticals and Alexion. The program's advancement will depend on Phase 2 data readout and subsequent regulatory strategy decisions regarding Phase 3 initiation or potential accelerated pathways.
Amyloidosis represents a significant unmet medical need with limited treatment options. The disease encompasses multiple subtypes with high morbidity and mortality, affecting cardiac, neurological, and systemic manifestations depending on the amyloid protein involved. Current approved therapies address specific amyloidosis subtypes, but treatment options remain limited, particularly for certain patient populations. The market for amyloidosis therapeutics is expanding as diagnostic capabilities improve and disease awareness increases among clinicians.
ZN-d5's development is clinically relevant given the progressive nature of amyloidosis and the need for disease-modifying therapies. Zentalis's entry into this space with a small-molecule approach diversifies the therapeutic modalities available, complementing existing RNA interference and monoclonal antibody approaches. The competitive landscape includes multiple Phase 3 programs from well-capitalized sponsors (Alnylam, Alexion), indicating strong commercial interest in the indication. Success of ZN-d5 would position Zentalis in a growing therapeutic area with significant commercial potential, particularly if the program demonstrates differentiated efficacy, safety, or patient convenience profiles compared to existing or emerging competitors.
Drug Class: Small-molecule therapeutic candidate
Modality: Small molecule
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Route of Administration: Not yet disclosed
Indication: Amyloidosis
Related Therapies: ZN-d5 is being developed in a therapeutic area that includes approved agents such as Vyndaqel (tafamidis, approved for transthyretin amyloidosis) and RNA interference therapeutics from Alnylam Pharmaceuticals targeting transthyretin and other amyloid precursor proteins. The specific amyloidosis subtype targeted by ZN-d5 has not been disclosed, limiting direct comparison to existing therapies.
Patent Status: Not yet disclosed
First Approval: Not applicable; program remains in clinical development
Also known as: amyloid, amyloid disease, amyloidoses, amyloidosis (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Korea, Republic of) — source: Orphanet, validated.
A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
ClinicalTrials.gov lists 132 registered studies for Amyloidosis (AACT aggregate).
Phase breakdown: NA (72), PHASE2 (24), PHASE1 (13), PHASE1/PHASE2 (10), PHASE3 (10), EARLY_PHASE1 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019065), Orphanet — amyloidosis, NCT00004374, NCT00017680, NCT00166413, NCT00186095, NCT00186407, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 trial completed
ZN-d5-003 Phase 2 trial (NCT05199337) in amyloidosis completed as of September 19, 2024.
ZN-d5 competes in an increasingly crowded amyloidosis therapeutic landscape. Approved therapies include Vyndaqel (tafamidis, 61 mg soft capsules) from Monte Rosa Therapeutics, which is indicated for transthyretin amyloidosis. Multiple Phase 3 programs are advancing from Alnylam Pharmaceuticals, including Amvuttra (vutrisiran), Nucresiran, Patisiran, and several investigational compounds (ALN-TTRSC04-004, ALN-TTR02-011, ALN-TTRSC02-002), predominantly targeting transthyretin-mediated amyloidosis. Alexion Europe is developing CAEL-101 (sodium chloride formulation), also in Phase 3. The competitive set reflects a focus on transthyretin amyloidosis, though the specific amyloidosis subtype targeted by ZN-d5 remains undisclosed, making precise competitive positioning unclear. Alnylam's portfolio dominance in RNA interference therapeutics for amyloidosis represents the primary competitive threat, though small-molecule approaches may offer advantages in tolerability, administration, or tissue penetration depending on ZN-d5's mechanism and profile.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Vyndaqel 61 mg soft capsules | Monte Rosa Therapeutics | small_molecule | approved |
| Tofacitinib and Acitretin Capsules. | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| SODIUM CHLORIDE , CAEL-101 | Alexion Europe SAS | small_molecule | phase_3 |
| Amvuttra 25 mg solution for injection in pre-filled syringe | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| Nucresiran | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| ALN-TTRSC04-004 | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| Patisiran | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| ALN-TTR02-011 | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| ALN-TTRSC02-002 | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| Neuraceq 300 MBq/mL solution for injection | Fondazione Telethon ETS | small_molecule | phase_3 |
| Placebo for Nucresiran, ALN-TTRSC04 | Alnylam Netherlands B.V. | small_molecule | phase_3 |
| VUTRISIRAN SODIUM | — | Transthyretin mRNA rnai inhibitor | Approved |
| VUTRISIRAN | — | Transthyretin mRNA rnai inhibitor | Approved |
| TAFAMIDIS MEGLUMINE | — | Transthyretin stabiliser | Approved |
| TAFAMIDIS | — | Transthyretin stabiliser | Approved |
| PATISIRAN SODIUM | — | Transthyretin mRNA RNAi inhibitor | Approved |
| INOTERSEN SODIUM | — | Transthyretin mRNA antisense inhibitor | Approved |
| THALIDOMIDE | — | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 3 |
| REVUSIRAN | — | Transthyretin mRNA RNAi inhibitor | Phase 3 |
| LENALIDOMIDE | — | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Not yet disclosed
EMA Status: Not yet disclosed
PMDA (Japan) Status: Not yet disclosed
NMPA (China) Status: Not yet disclosed
ZN-d5 remains in Phase 2 clinical development with no disclosed regulatory interactions, breakthrough designations, or accelerated pathway designations. Regulatory strategy and timelines for potential Phase 3 initiation or regulatory submissions have not been announced. The program's regulatory path will likely depend on Phase 2 efficacy, safety, and biomarker data, as well as the specific amyloidosis subtype being targeted.
ZN-d5 is being developed for the treatment of amyloidosis, a rare disease characterized by abnormal protein folding and tissue accumulation. The specific amyloidosis subtype targeted has not been disclosed.
No. ZN-d5 is currently in Phase 2 clinical development. No regulatory approval has been granted, and no accelerated or breakthrough designations have been disclosed.
ZN-d5 is developed by Zentalis Pharmaceuticals. No manufacturing partners or licensing arrangements have been disclosed.
The mechanism of action for ZN-d5 has not been disclosed. It is classified as a small-molecule therapeutic, but its specific molecular target and biological pathway remain undisclosed.
The molecular target of ZN-d5 has not been disclosed by Zentalis Pharmaceuticals.
ZN-d5 has completed a Phase 2 trial (NCT05199337) in amyloidosis as of September 19, 2024. Detailed trial results have not yet been reported.
The route of administration for ZN-d5 has not been disclosed.
ZN-d5 is in Phase 2 development. The Phase 2 trial (NCT05199337) was completed as of September 19, 2024.
No partnership has been disclosed. Zentalis Pharmaceuticals is developing ZN-d5 independently.
Competitors include approved therapies such as Vyndaqel (tafamidis) and multiple Phase 3 programs from Alnylam Pharmaceuticals (Amvuttra, Nucresiran, Patisiran) and Alexion (CAEL-101), primarily targeting transthyretin amyloidosis.
The Phase 2 trial was completed on September 19, 2024, but detailed results have not yet been publicly disclosed. Timing of data presentation or publication has not been announced.
Patent information for ZN-d5 has not been disclosed.
The specific amyloidosis subtype targeted by ZN-d5 has not been disclosed, so it is unclear whether it targets transthyretin or another amyloid protein.
Projected peak sales figures for ZN-d5 have not been disclosed by Zentalis or analysts.
No breakthrough therapy designation or other accelerated regulatory pathway designation has been disclosed for ZN-d5.
The internal development code for the Phase 2 trial is ZN-d5-003.
ZN-d5 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Zentalis's pursuit of amyloidosis without a disclosed partnership suggests confidence in ZN-d5's potential or a strategic decision to retain full commercial rights. The Phase 2 completion is a critical inflection point; data readout will determine whether the program advances to Phase 3 or requires optimization.
Competitive Implications: ZN-d5's small-molecule modality differentiates it from the RNA interference-dominated competitive set led by Alnylam. However, Alnylam's multiple Phase 3 programs and approved therapies create a high bar for market entry. ZN-d5's success will depend on demonstrating superior efficacy, safety, convenience, or applicability to amyloidosis subtypes underserved by existing therapies.
Future Catalysts: Near-term catalyst is Phase 2 data disclosure, including efficacy endpoints, safety profile, and biomarker data. Subsequent catalysts include Phase 3 initiation announcement, interim efficacy readouts, and regulatory interactions. The timing and content of the Phase 2 data readout will be critical for investor and clinical community assessment of the program's viability.
Expected Milestones: Phase 2 data presentation or publication expected in coming months; Phase 3 initiation (if warranted) likely in 2025; regulatory submission timeline dependent on Phase 3 outcomes and competitive dynamics.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.